| Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
| Veids | Finanšu pārskati |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2011-05-27 17:02:02 |
| Versijas komentārs | Financial results attached. |
| Teksts |
Today, on 27 May, the financial statement of the JSC
“Grindeks” on the first quarter of the year 2011 submitted to
“NASDAQ OMX Riga” indicates that the net profit of the Group of
“Grindeks” (hereinafter – the Group) was 1.5 million lats in the
reporting period, which is by 0.1 million lats or 7.1% more in
comparison with the first three months of 2010. In its turn, the
Group’s turnover during the first quarter of 2011 amounted to 14
million lats, which is by 0.55 million lats or 4.1% more than in
the first quarter of 2010.
In the first three months of 2011, the gross profit
margin of the Group was 57.9%, whereas, the net profit margin
comprised 10.7%. Products of the Group, manufactured during the
reporting period, were exported to 41 countries worldwide for the
total amount of 13.2 million lats.
In the first quarter of 2011 the sales volume of the
final dosage forms of “Grindeks” amounted to 12.45 million lats,
which is by 0.17 million lats or 1.4% more than in the same
reporting period of 2010. In the first quarter of 2011, the amount
of “Grindeks” final dosage forms’ export to the main markets –
Russia, other CIS countries and Georgia – remained at the level of
the last year’s first quarter and was 10.4 million lats. In its
turn, the turnover of the final dosage forms in the Baltic States
and other European countries reached 2.05 million lats, which is by
0.32 million lats or 18.5% more than in the first quarter of
2010.
In the first three months of 2011 the active
pharmaceutical ingredients’ sales volume reached 1.55 million lats,
which is by 0.38 million lats or 32.5% more than in the first
quarter of 2010. The main export markets for active pharmaceutical
ingredients of “Grindeks” are Germany, Japan and the Netherlands.
Along with the most demanded active pharmaceutical ingredients –
detomidine, medetomidine, atipamezole etc. – the most significant
increase in demand observed for the active pharmaceutical
ingredient – ursodeoxycholic acid (UDCA), which was introduced into
manufacturing in 2009.
“Grindeks” Member of the Board, Finance and
Administrative Director Vadims Rabša: “In the pharmaceutical market
the competition is fierce, and there are no reasons to
believe that it could decrease. Our results confirm that we are
able to use our advantages and we are ready for
challenges to achieve a positive growth in
business indicators. In our traditional markets –
Russia and other CIS countries – the demand for our ready made
medications is stable. But in the new markets of Eastern Europe and
the Balkans, as well as of the Baltic countries a long-term
positive trend and dynamic growth have been already
observed. Business of active pharmaceutical
ingredients takes a larger and larger role, and it indicates two
strategic priorities set before - business diversification and
targeted direction towards vertically integrated solutions. It
enhances the competence and is an important prerequisite for
competitiveness!”
On
“Grindeks”
“Grindeks” is the leading pharmaceutical company in the
Baltic States. Its main fields of action are: research,
development, manufacturing and sale of original products, generics
and active pharmaceutical ingredients. “Grindeks” specializes in
the heart and cardiovascular, CNS and anti-cancer medication
therapeutic groups.
The Group consists of four subsidiary companies in
Latvia, Estonia and Russia, as well representative offices in ten
countries. Products of the company are exported to 50 countries and
its export comprises more than 95% of the total turnover. The main
markets are: Russia and other CIS countries, the Baltic
States, Germany and the
Netherlands. JSC “Grindeks” shares are listed in the
Official List of “NASDAQ
OMXRiga”.
Further information on the company –
www.grindeks.lv
Further information:
Laila Klavina
Head of the Communications Department
JSC “Grindeks”
Phones: (+371) 67083370, (+371)
29256012
Fax: (+371) 67083505
E-mail: laila.klavina@grindeks.lv
|
| Pielikumi |